Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Open Label Exploratory, Safety and Tolerability Study With PP100-01 in Patients Treated With the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose (The POP Trial)

Next Previous
Trial Profile

A Randomised Open Label Exploratory, Safety and Tolerability Study With PP100-01 in Patients Treated With the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose (The POP Trial)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acetylcysteine (Primary) ; Calmangafodipir (Primary)
  • Indications Drug toxicity; Liver failure; Liver injury
  • Focus Adverse reactions; Proof of concept
  • Acronyms POP
  • Sponsors Egetis Therapeutics; PledPharma

Most Recent Events

  • 21 Aug 2019 According to a PledPharma media release, results of this study were recognized as one of the highlights at one of the worlds largest liver conferences, European Association of the Study of the Liver International Liver Congress (EASL ILC, April 2019).
  • 15 Jul 2019 According to a PledPharma media release, data from this study was published in the Lancets EBioMedicine research journal.
  • 15 Jul 2019 Results published in the PledPharma Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top